Form 4 for AEON AEON Biopharma, Inc.
Accepted 2023-08-14 00:00:00 ET · period of report 2023-08-11 · accession 0001477932-23-006094 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-08-14 | 2023-08-11 | AEON | Strathspey Crown Holdings Group, LLC | 10% | S - Sale | $10.00 | -7.38M | 2.03M | -78% | -$73.80M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Class A Common Stock | 2023-08-11 | S | D | 7,380,394 | $10.00 | 2,031,773 | D | — | — | (F1) Reflects the disposition of shares of the Issuer's Class A Common Stock (the "Distributed Shares") by the Reporting Person in connection with the repurchase of certain of the Reporting Person's membership interests held by its members in exchange for, among other consideration, the Distributed Shares. (F2) In addition to the disposition of the Distributed Shares, the amount reflected includes a reduction in the Reporting Person's beneficial ownership by an additional 8,203 shares of the Issuer's Class A Common Stock to correct an inadvertent overstatement of such ownership by such amount in the Reporting Person's Form 3 filed with the Securities and Exchange Commission on July 31, 2023. |